Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates GLUE Bullish with a Setup Score of 65, net conviction 43, actionability 97. How the Setup Score works →
| Total Setup Score | 65 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 43 |
| Actionability | 97 (in range) |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflamma… Read full Trend Edge analysis →
| Current Price | $14.38 |
|---|---|
| Market Cap | $1.26B |
| Float | 54.5M |
| Shares Outstanding | 85.3M |
| P/E (Forward) | 10.86 |
| Price/Sales (TTM) | 43.89 |
| vs. Analyst Target | +98.2% to analyst PT |
| Operating Margin (TTM) | -547.84% |
| Revenue (TTM) | $28.7M |
| Dividend Rate | None |
| Analyst Target Price | $28.50 (9 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | N/A | -$35.9M | -$537,000 | -$27.5M |
| 2021 | N/A | -$74.0M | -$2.1M | -$71.8M |
| 2022 | N/A | -$109M | -$8.6M | -$101M |
| 2023 | N/A | -$135M | -$6.2M | -$129M |
| 2024 | $75.6M | -$72.7M | $67.5M | -$62.0M |
| 2025 | $124M | -$38.6M | $115M | -$31.4M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | $12.8M | -$27.1M |
| Dec 2025 | $2.8M | -$46.1M |
| Mar 2026 | $4.2M | -$44.5M |
| Jun 2026 | $9.0M | -$43.4M |
| Insider Ownership | 0.6% |
|---|---|
| Institutional Ownership | 115.7% |
| Short Float | 30.2% |
| % of All Funds Holding | 2.18% |
| Number of Funds Holding | 192 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $19.35 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $18.59 | Medium-term trend |
| Weekly | 80-Week SMA | $12.48 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $8.67 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $18.05 | Near-term monthly trend |
| Monthly | 20-Month SMA | $12.05 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $8.97 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $23.80 | resistance | 1.20x | 0 months ago |
| $12.80 | support | 1.06x | 8 months ago |
| $7.40 | support | 1.58x | 9 months ago |
| $4.80 | support | 2.69x | 10 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.01% | 0.00% | 40.91% | 3.61% | -2.22% |
| 1 Day | 0.92% | -0.27% | 50.00% | 13.38% | -6.37% |
| 1 Week | 1.88% | 0.10% | 50.00% | 26.60% | -20.51% |
| 2 Weeks | 2.78% | 0.34% | 50.00% | 59.05% | -21.81% |
| 1 Month | 7.04% | 0.43% | 52.38% | 56.28% | -24.82% |
Next earnings: October 25, 2026 (59 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | 0.38% | 46.3% | 242 |
| Tuesday | 0.31% | 50.7% | 268 |
| Wednesday | 0.20% | 50.0% | 266 |
| Thursday | -0.12% | 47.1% | 259 |
| Friday | -0.00% | 46.0% | 261 |
Institutional holder breakdown coming soon.
Total institutional ownership: 115.7%
Total insider ownership: 0.6%
Founder-led management: Markus Warmuth (President, CEO & Director), Sharon Townson (Chief Scientific Officer), John Castle (Chief Data & Information Officer), Filip Janku (Chief Medical Officer), Phil Nickson (Chief Business & Legal Officer), Magnus Walter (Senior Vice President of Drug Discovery)
| Total Filings | 30 |
|---|---|
| Net Value | -$2.8M |
| Net Shares Change | 135,349 |
| % of Float | 0.2% |
| C-Suite Filings | 28 |
| Clusters Detected | 5 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Warmuth Markus | President & CEO | -$515,091.3 | 3 | 3 sell |
| Manning Anthony M. | -$189,500 | 1 | 1 sell | |
| Janku Filip | Chief Medical Officer | -$179,160.69 | 1 | 1 sell |
| Nickson Philip | Chief Business & Legal Officer | -$151,274.012 | 2 | 2 sell |
| Dunn Edmund | Principal Accounting Officer | -$122,746.74 | 2 | 2 sell |
| Townson Sharon | Chief Scientific Officer | -$47,861.35 | 1 | 1 sell |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-01-05 – 2026-01-09 | 7 | 6 | -$481,348.396 | 7 C-suite |
| 2026-02-24 – 2026-03-05 | 4 | 3 | -$399,881.653 | 4 C-suite |
| 2026-05-22 – 2026-06-02 | 5 | 4 | -$394,660.047 | 4 C-suite |
| 2026-06-18 – 2026-07-01 | 8 | 4 | -$1.1M | 7 C-suite |
| 2026-07-07 – 2026-07-17 | 3 | 3 | -$407,640.631 | 3 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-07-17 | Warmuth Markus | President & CEO | -$220,218.55 | Transaction at $23.18, now -38.0% |
| 2026-06-30 | Manning Anthony M. | -$189,500 | Transaction at $13.63, now +5.5% | |
| 2026-04-10 | Nickson Philip | Chief Business & Legal Officer | -$103,412.662 | Transaction at $17.69, now -18.7% |
| 2026-04-15 | Warmuth Markus | President & CEO | -$141,124.8 | Transaction at $17.64, now -18.5% |
| 2026-03-05 | Dunn Edmund | Principal Accounting Officer | -$2,496.44 | Transaction at $17.96, now -19.9% |
| 2026-03-02 | Dunn Edmund | Principal Accounting Officer | -$120,250.3 | Transaction at $15.75, now -8.7% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Monte Rosa Therapeutics Inc (GLUE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for GLUE on Trend Edge →